Skip to content
Study details
Enrolling now

64Cu-SAR-bisPSMA Trial for Prostate Cancer

Clarity Pharmaceuticals Ltd
NCT IDNCT06970847ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

220

Study length

about 1.6 years

Ages

18+

Sex

Male only

Locations

24 sites in AR, AZ, CA +15

About this study

Researchers are testing whether 64Cu-SAR-bisPSMA can help find prostate cancer that has returned after treatment. The trial will involve men with prostate cancer who have had previous treatments like surgery, radiation, or brachytherapy. Participants will be followed for about a year and a half.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take 64Cu-SAR-bisPSMA
PhasePhase 3

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low7%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Secondary: To determine the efficacy of 64Cu-SAR-bisPSMA PET/CT in participants with negative or equivocal conventional imaging at baseline, To investigate the safety and tolerability of 64-CuSAR-bisPSMA

Body systems

Oncology